ES2162937T3 - Preparado combinado para su aplicacion en enfermedades inmunologicas. - Google Patents

Preparado combinado para su aplicacion en enfermedades inmunologicas.

Info

Publication number
ES2162937T3
ES2162937T3 ES95930441T ES95930441T ES2162937T3 ES 2162937 T3 ES2162937 T3 ES 2162937T3 ES 95930441 T ES95930441 T ES 95930441T ES 95930441 T ES95930441 T ES 95930441T ES 2162937 T3 ES2162937 T3 ES 2162937T3
Authority
ES
Spain
Prior art keywords
combined preparation
immunological diseases
application
pentoxifilina
diltiazem
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95930441T
Other languages
English (en)
Inventor
Martin Schonharting
Stefan Mullner
Peter Zabel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hoechst AG
Original Assignee
Hoechst AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst AG filed Critical Hoechst AG
Application granted granted Critical
Publication of ES2162937T3 publication Critical patent/ES2162937T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

UN PREPARADO COMBINADO, CONTENIENDO UN COMPUESTO, QUE POSEE UN EFECTO INHIBIDOR DE LA FOSFODIESTERASA, Y UN COMPUESTO QUE DISMINUYE EL CONTENIDO BIOLOGICAMENTE EFECTIVO DE CA{SUP,2+} INTRACELULAR; ESTA INDICADO PARA EL TRATAMIENTO DE ENFERMEDADES INMUNOLOGICAS. EJEMPLOS PARA ESTO SON LAS SIGUIENTES COMBINACIONES: PENTOXIFILINA Y NIFEDIPINA, PENTOXIFILINA Y DILTIAZEM, PENTOXIFILINA Y VERAPAMIL, PENTOXIFILINA Y CICLOSPORINA A, Y VINPOCETINA Y DILTIAZEM.
ES95930441T 1994-08-25 1995-08-07 Preparado combinado para su aplicacion en enfermedades inmunologicas. Expired - Lifetime ES2162937T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4430128A DE4430128A1 (de) 1994-08-25 1994-08-25 Kombinationspräparat mit immunsuppressiven, kardiovaskulären und cerebralen Wirkungen

Publications (1)

Publication Number Publication Date
ES2162937T3 true ES2162937T3 (es) 2002-01-16

Family

ID=6526515

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95930441T Expired - Lifetime ES2162937T3 (es) 1994-08-25 1995-08-07 Preparado combinado para su aplicacion en enfermedades inmunologicas.

Country Status (12)

Country Link
US (2) US5990103A (es)
EP (1) EP0777482B1 (es)
JP (1) JPH10504550A (es)
AT (1) ATE208620T1 (es)
AU (1) AU697311B2 (es)
DE (2) DE4430128A1 (es)
DK (1) DK0777482T3 (es)
ES (1) ES2162937T3 (es)
FI (1) FI970747A7 (es)
MX (1) MX9701385A (es)
PT (1) PT777482E (es)
WO (1) WO1996005838A2 (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6294350B1 (en) * 1997-06-05 2001-09-25 Dalhousie University Methods for treating fibroproliferative diseases
CA2334120C (en) * 1998-08-10 2006-10-17 Asahi Kasei Kogyo Kabushiki Kaisha Oral sustained-release preparation of fasudil hydrochloride
US6368815B1 (en) * 1999-03-29 2002-04-09 Warner-Lambert Company Screening of molecules that inhibit human phosphodiesterase 4A produced by non-recombinant cell lines
ES2208310T3 (es) * 1999-03-31 2004-06-16 Vernalis Limited Derivados de pirimido(6,1-a) isoquinolin-4-ona.
CN100494182C (zh) * 2000-05-12 2009-06-03 基酶有限公司 肿瘤坏死α因子信号的调节因子
US7470718B2 (en) * 2000-10-03 2008-12-30 Albert Einstein College Of Medicine Of Yeshiva University Method for treating a demyelinating condition
EP1426051B1 (en) * 2001-09-11 2008-07-16 Asahi Kasei Pharma Corporation Medicinal composition for prevention of or treatment for cerebrovascular disorder
ATE502642T1 (de) * 2001-10-05 2011-04-15 Zalicus Inc Kombinationen für die behandlung von immun- entzündlichen erkrankungen
DE10226420A1 (de) * 2002-06-13 2004-01-15 Eucro European Contract Research Gmbh & Co Kg Verfahren zur Behandlung der Artherosklerose
WO2004037183A2 (en) * 2002-10-22 2004-05-06 Harbor-Ucla Research And Education Institute Phosphodiester inhibitors and nitric oxide modulators for treating peyronie’s disease, arteriosclerosis and other fibrotic diseases
US8133903B2 (en) * 2003-10-21 2012-03-13 Los Angeles Biomedical Research Institute at Harbor—UCLA Medical Center Methods of use of inhibitors of phosphodiesterases and modulators of nitric oxide, reactive oxygen species, and metalloproteinases in the treatment of peyronie's disease, arteriosclerosis and other fibrotic diseases
ATE493980T1 (de) * 2002-11-21 2011-01-15 Genzyme Corp Verwendung eines diamidderivats zur verhinderung der chronischen transplantatabstossung
AU2003291143A1 (en) * 2002-11-21 2004-06-18 Genzyme Corporation Combination of diamide derivatives and immunosuppressive agents for induction of immune tolerance
US20040147534A1 (en) * 2003-01-23 2004-07-29 Foote Mary Ann Topical composition and method for treating occlusive wounds
US20040241234A1 (en) * 2003-06-02 2004-12-02 Alpharma, Inc. Controlled release press-coated formulations of water-soluble active agents
TW200517114A (en) * 2003-10-15 2005-06-01 Combinatorx Inc Methods and reagents for the treatment of immunoinflammatory disorders
WO2006054536A1 (ja) * 2004-11-16 2006-05-26 Nippon Shinyaku Co., Ltd. 尿路結石症治療剤
US20060269579A1 (en) * 2005-05-25 2006-11-30 Musculoskeletal Research Llc Compositions for treating osteoarthritis
US7767710B2 (en) * 2005-05-25 2010-08-03 Calosyn Pharma, Inc. Method for treating osteoarthritis
CA2652773A1 (en) * 2006-05-22 2007-12-06 Combinatorx, Incorporated Methods and compositions for the treatment of diseases or conditions associated with increased c-reactive protein, interleukin-6, or interferon-gamma levels
CA2737131A1 (en) * 2007-09-19 2009-03-26 Zalicus Inc. Therapeutic regimens for the treatment of immunoinflammatory disorders
WO2009042854A1 (en) * 2007-09-26 2009-04-02 Musculoskeletal Research Llc Ion-channel regulator compositions and methods of using same
KR20100121601A (ko) * 2007-12-17 2010-11-18 콤비네이토릭스, 인코포레이티드 면역염증성 질환의 치료를 위한 치료요법
KR20100121527A (ko) 2008-02-29 2010-11-17 콘서트 파마슈티컬즈, 인크. 치환된 잔틴 유도체
US20110053961A1 (en) 2009-02-27 2011-03-03 Concert Pharmaceuticals, Inc. Substituted xanthine derivatives
WO2013013052A1 (en) 2011-07-19 2013-01-24 Concert Pharmaceuticals, Inc. Substituted xanthine derivatives
IN2014DN08443A (es) 2012-04-13 2015-05-08 Concert Pharmaceuticals Inc
US20170216296A1 (en) 2014-04-18 2017-08-03 Concert Pharmaceuticals, Inc. Methods of treating hyperglycemia
CN111840287A (zh) * 2019-04-30 2020-10-30 健艾仕生物医药有限公司 化合物在治疗炎症引起的自身免疫性皮肤病中的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI870731L (fi) * 1985-07-02 1987-02-20 Key Pharma Foerfarande och blandning foer behandling av kronisk obstruktiv lungaokomma.
DE3604149A1 (de) * 1986-02-10 1987-08-13 Rentschler Arzneimittel Arzneimittelkombination
EP0493682A3 (en) * 1990-11-30 1992-11-19 Hoechst-Roussel Pharmaceuticals Incorporated Use of xanthines for the preparation of a medicament effective for inhibiting the effects of allograft reaction in humans
EP0490181A1 (en) * 1990-11-30 1992-06-17 Hoechst-Roussel Pharmaceuticals Incorporated Use of xanthines for preparation of a medicament having immunosuppressing activity
IL99368A (en) * 1991-09-02 1996-01-19 Teva Pharma Preparations for the treatment of psoriasis and atopic dermatitis, which contain the result of xanthine
US5190972A (en) * 1992-01-27 1993-03-02 The University Of Melbourne Method of combatting cyclosporine organ toxicity with prostaglandin analogs
DE69332634T2 (de) * 1992-03-04 2003-05-08 Cell Therapeutics, Inc. Enantiomere hydroxylierte xanthinverbindungen
JPH07508030A (ja) * 1992-05-13 1995-09-07 アルコン　ラボラトリーズ，インコーポレイテッド カルシウムアンタゴニストと公知の抗緑内障薬との組合せを含む眼局所用組成物
US5670506A (en) * 1993-04-05 1997-09-23 Cell Therapeutics, Inc. Halogen, isothiocyanate or azide substituted xanthines

Also Published As

Publication number Publication date
FI970747L (fi) 1997-02-21
EP0777482A1 (de) 1997-06-11
FI970747A0 (fi) 1997-02-21
US6337325B1 (en) 2002-01-08
DE59509848D1 (de) 2001-12-20
AU697311B2 (en) 1998-10-01
AU3382995A (en) 1996-03-14
ATE208620T1 (de) 2001-11-15
EP0777482B1 (de) 2001-11-14
US5990103A (en) 1999-11-23
WO1996005838A3 (de) 1996-04-11
MX9701385A (es) 1997-05-31
WO1996005838A2 (de) 1996-02-29
DK0777482T3 (da) 2002-02-18
JPH10504550A (ja) 1998-05-06
PT777482E (pt) 2002-04-29
FI970747A7 (fi) 1997-02-21
DE4430128A1 (de) 1996-02-29

Similar Documents

Publication Publication Date Title
ES2162937T3 (es) Preparado combinado para su aplicacion en enfermedades inmunologicas.
MX9705710A (es) Compuestos con propiedades de liberacion de la hormona del crecimiento.
MX9704097A (es) Induccion de respuestas de linfocitos t citotoxicos.
MX9709278A (es) Dipeptidos que promueven la liberacion de la hormona de crecimiento, composiciones que los contienen y uso de los mismos.
ES2187642T3 (es) Compuestos de carbamato triciclicos utiles para la inhibicion de la funcion de la proteina g y para el tratamiento de enfermedades proliferativas.
AR005987A1 (es) Terapia combinada para la osteoporosis
ES2190803T3 (es) Iminas ciclicas como pesticidas.
EA200000994A1 (ru) Применение кабэрголина при лечении синдрома усталых ног
ES2113527T3 (es) Agente para regulacion de la condicion grasa de la piel.
ES2117052T3 (es) Induccion de respuestas de linfocitos t citotoxicos.
SV1995000007A (es) Derivados del acido micofenolico 5-substituidos.
ES2183140T3 (es) Combinaciones, que tienen efectos inmunosupresores, que contienen un inhibidor de ciclooxigenasa-2 y un inhibidor de leucotrieno a4 hidrolasa.
AR003119A1 (es) Composicion farmaceutica para tratar infecciones virosicas o inhibir el crecimiento de tumores o canceres que comprenden una mezcla de un n- clorofenilcarbamato o un n- clorofeniltiocarbamato y un n- fosfonoglicina y uso de dicha composicion farmaceutica para la manufactura de un medicamento para tratar infecciones virosicas o inhibir el crecimiento de tumores o canceres
DE69801660D1 (de) Lokale behandlung von psoriasis unter verwendung neutralisierender antikörper gegen il-8
AR016981A2 (es) Polipeptidos sinteticos
AR044235A2 (es) Uso de una composicion que comprende merozoitos de eimeria vivos
ES2194104T3 (es) Uso de selegilina para el tratamiento de la perdida de audicion en mamiferos.
ES2120667T3 (es) Sal de l-carnitina y composiciones cosmeticas y farmaceuticas que la contienen para tratamiento de dermatosis.
ES2082074T3 (es) 1,3-difenil-2-propin-1-onas.
ES2066096T3 (es) 4-bencil-5-fenil-2,4-dihidro-3h-1,2,4-triazol-3-onas y su uso como anticonvulsivos.
NO941097D0 (no) Hudregenererende kosmetisk preparat
ES2189206T3 (es) Beta-alcoxiacrilatos contra la malaria.
BR0012006A (pt) Método para evitar inflamações, doenças autoimunes e crescimento de tumor, e, uso de substâncias que suprimem a ativação mediada por ltbr
HUP9701618A2 (hu) Tramadolt és valamely kálciumcsatorna antagonistát tartalmazó gyógyászati készítmény
ES2058349T3 (es) Utilizacion de betabloqueadores para el tratamiento de la progresion de la miopia axial infantil.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 777482

Country of ref document: ES